Cargando…

Machine Learning for Prediction of Immunotherapy Efficacy in Non-Small Cell Lung Cancer from Simple Clinical and Biological Data

SIMPLE SUMMARY: We studied determinants of response to immune-checkpoint inhibition in advanced non-small cell lung cancer patients. Specifically, we evaluated the association with response of multiple simple pre-treatment blood markers available from routine examination. We first used classical sta...

Descripción completa

Detalles Bibliográficos
Autores principales: Benzekry, Sébastien, Grangeon, Mathieu, Karlsen, Mélanie, Alexa, Maria, Bicalho-Frazeto, Isabella, Chaleat, Solène, Tomasini, Pascale, Barbolosi, Dominique, Barlesi, Fabrice, Greillier, Laurent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8699503/
https://www.ncbi.nlm.nih.gov/pubmed/34944830
http://dx.doi.org/10.3390/cancers13246210
_version_ 1784620528963682304
author Benzekry, Sébastien
Grangeon, Mathieu
Karlsen, Mélanie
Alexa, Maria
Bicalho-Frazeto, Isabella
Chaleat, Solène
Tomasini, Pascale
Barbolosi, Dominique
Barlesi, Fabrice
Greillier, Laurent
author_facet Benzekry, Sébastien
Grangeon, Mathieu
Karlsen, Mélanie
Alexa, Maria
Bicalho-Frazeto, Isabella
Chaleat, Solène
Tomasini, Pascale
Barbolosi, Dominique
Barlesi, Fabrice
Greillier, Laurent
author_sort Benzekry, Sébastien
collection PubMed
description SIMPLE SUMMARY: We studied determinants of response to immune-checkpoint inhibition in advanced non-small cell lung cancer patients. Specifically, we evaluated the association with response of multiple simple pre-treatment blood markers available from routine examination. We first used classical statistical tools and then developed a machine learning algorithm for individual predictions. We obtained a 69% accuracy. Hemoglobin levels and performance status were the strongest predictors. Neutrophil-to-lymphocyte ratio was also associated with outcome. A benchmark of 8 machine learning models also evidenced that the best model performed almost equally well than a logistic regression (basic statistical learning model). ABSTRACT: Background: Immune checkpoint inhibitors (ICIs) are now a therapeutic standard in advanced non-small cell lung cancer (NSCLC), but strong predictive markers for ICIs efficacy are still lacking. We evaluated machine learning models built on simple clinical and biological data to individually predict response to ICIs. Methods: Patients with metastatic NSCLC who received ICI in second line or later were included. We collected clinical and hematological data and studied the association of this data with disease control rate (DCR), progression free survival (PFS) and overall survival (OS). Multiple machine learning (ML) algorithms were assessed for their ability to predict response. Results: Overall, 298 patients were enrolled. The overall response rate and DCR were 15.3% and 53%, respectively. Median PFS and OS were 3.3 and 11.4 months, respectively. In multivariable analysis, DCR was significantly associated with performance status (PS) and hemoglobin level (OR 0.58, p < 0.0001; OR 1.8, p < 0.001). These variables were also associated with PFS and OS and ranked top in random forest-based feature importance. Neutrophil-to-lymphocyte ratio was also associated with DCR, PFS and OS. The best ML algorithm was a random forest. It could predict DCR with satisfactory efficacy based on these three variables. Ten-fold cross-validated performances were: accuracy 0.68 ± 0.04, sensitivity 0.58 ± 0.08; specificity 0.78 ± 0.06; positive predictive value 0.70 ± 0.08; negative predictive value 0.68 ± 0.06; AUC 0.74 ± 0.03. Conclusion: Combination of simple clinical and biological data could accurately predict disease control rate at the individual level.
format Online
Article
Text
id pubmed-8699503
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-86995032021-12-24 Machine Learning for Prediction of Immunotherapy Efficacy in Non-Small Cell Lung Cancer from Simple Clinical and Biological Data Benzekry, Sébastien Grangeon, Mathieu Karlsen, Mélanie Alexa, Maria Bicalho-Frazeto, Isabella Chaleat, Solène Tomasini, Pascale Barbolosi, Dominique Barlesi, Fabrice Greillier, Laurent Cancers (Basel) Article SIMPLE SUMMARY: We studied determinants of response to immune-checkpoint inhibition in advanced non-small cell lung cancer patients. Specifically, we evaluated the association with response of multiple simple pre-treatment blood markers available from routine examination. We first used classical statistical tools and then developed a machine learning algorithm for individual predictions. We obtained a 69% accuracy. Hemoglobin levels and performance status were the strongest predictors. Neutrophil-to-lymphocyte ratio was also associated with outcome. A benchmark of 8 machine learning models also evidenced that the best model performed almost equally well than a logistic regression (basic statistical learning model). ABSTRACT: Background: Immune checkpoint inhibitors (ICIs) are now a therapeutic standard in advanced non-small cell lung cancer (NSCLC), but strong predictive markers for ICIs efficacy are still lacking. We evaluated machine learning models built on simple clinical and biological data to individually predict response to ICIs. Methods: Patients with metastatic NSCLC who received ICI in second line or later were included. We collected clinical and hematological data and studied the association of this data with disease control rate (DCR), progression free survival (PFS) and overall survival (OS). Multiple machine learning (ML) algorithms were assessed for their ability to predict response. Results: Overall, 298 patients were enrolled. The overall response rate and DCR were 15.3% and 53%, respectively. Median PFS and OS were 3.3 and 11.4 months, respectively. In multivariable analysis, DCR was significantly associated with performance status (PS) and hemoglobin level (OR 0.58, p < 0.0001; OR 1.8, p < 0.001). These variables were also associated with PFS and OS and ranked top in random forest-based feature importance. Neutrophil-to-lymphocyte ratio was also associated with DCR, PFS and OS. The best ML algorithm was a random forest. It could predict DCR with satisfactory efficacy based on these three variables. Ten-fold cross-validated performances were: accuracy 0.68 ± 0.04, sensitivity 0.58 ± 0.08; specificity 0.78 ± 0.06; positive predictive value 0.70 ± 0.08; negative predictive value 0.68 ± 0.06; AUC 0.74 ± 0.03. Conclusion: Combination of simple clinical and biological data could accurately predict disease control rate at the individual level. MDPI 2021-12-09 /pmc/articles/PMC8699503/ /pubmed/34944830 http://dx.doi.org/10.3390/cancers13246210 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Benzekry, Sébastien
Grangeon, Mathieu
Karlsen, Mélanie
Alexa, Maria
Bicalho-Frazeto, Isabella
Chaleat, Solène
Tomasini, Pascale
Barbolosi, Dominique
Barlesi, Fabrice
Greillier, Laurent
Machine Learning for Prediction of Immunotherapy Efficacy in Non-Small Cell Lung Cancer from Simple Clinical and Biological Data
title Machine Learning for Prediction of Immunotherapy Efficacy in Non-Small Cell Lung Cancer from Simple Clinical and Biological Data
title_full Machine Learning for Prediction of Immunotherapy Efficacy in Non-Small Cell Lung Cancer from Simple Clinical and Biological Data
title_fullStr Machine Learning for Prediction of Immunotherapy Efficacy in Non-Small Cell Lung Cancer from Simple Clinical and Biological Data
title_full_unstemmed Machine Learning for Prediction of Immunotherapy Efficacy in Non-Small Cell Lung Cancer from Simple Clinical and Biological Data
title_short Machine Learning for Prediction of Immunotherapy Efficacy in Non-Small Cell Lung Cancer from Simple Clinical and Biological Data
title_sort machine learning for prediction of immunotherapy efficacy in non-small cell lung cancer from simple clinical and biological data
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8699503/
https://www.ncbi.nlm.nih.gov/pubmed/34944830
http://dx.doi.org/10.3390/cancers13246210
work_keys_str_mv AT benzekrysebastien machinelearningforpredictionofimmunotherapyefficacyinnonsmallcelllungcancerfromsimpleclinicalandbiologicaldata
AT grangeonmathieu machinelearningforpredictionofimmunotherapyefficacyinnonsmallcelllungcancerfromsimpleclinicalandbiologicaldata
AT karlsenmelanie machinelearningforpredictionofimmunotherapyefficacyinnonsmallcelllungcancerfromsimpleclinicalandbiologicaldata
AT alexamaria machinelearningforpredictionofimmunotherapyefficacyinnonsmallcelllungcancerfromsimpleclinicalandbiologicaldata
AT bicalhofrazetoisabella machinelearningforpredictionofimmunotherapyefficacyinnonsmallcelllungcancerfromsimpleclinicalandbiologicaldata
AT chaleatsolene machinelearningforpredictionofimmunotherapyefficacyinnonsmallcelllungcancerfromsimpleclinicalandbiologicaldata
AT tomasinipascale machinelearningforpredictionofimmunotherapyefficacyinnonsmallcelllungcancerfromsimpleclinicalandbiologicaldata
AT barbolosidominique machinelearningforpredictionofimmunotherapyefficacyinnonsmallcelllungcancerfromsimpleclinicalandbiologicaldata
AT barlesifabrice machinelearningforpredictionofimmunotherapyefficacyinnonsmallcelllungcancerfromsimpleclinicalandbiologicaldata
AT greillierlaurent machinelearningforpredictionofimmunotherapyefficacyinnonsmallcelllungcancerfromsimpleclinicalandbiologicaldata